Inclusion Criteria
* Discontinuous pulmonary arteries requiring conduit placement.
* Normal branch pulmonary arteries, with no evidence of hypoplasia or stenosis of distal branches of pulmonary arteries, measured from the hilar pulmonary artery.
* No evidence of pruning, lack of pulmonary artery lung distribution, evidence of focal stenosis, aortopulmonary collaterals or filling defects.
* The proximal portion of the targeted parenchymal pulmonary artery has a minimum diameter of 4mm.
* No history of systemic-pulmonary shunt placement.
* Age 6 months - 2 years (to maximize direct patient benefit).
* Weight \>5 kg
* Values within normal range (MN Children's values, considered universal)
* Participant must have biventricular heart with no hypoplasia of either the left or right ventricle.
* Written informed consent obtained from a parent or legal guardian.
* Caregivers must be willing and able to adhere to protocol requirements, including follow-up visits.
Exclusion Criteria
* Other congenital cardiac abnormalities that could interfere with graft placement or function
* Allergy to bovine proteins
* Allergy to aspirin
* Platelet count \< 100,000
* Extra-cardiac illness that is expected to limit survival to less than 24 months
* Previous operations directly involving the pulmonary arteries and/or a previous median sternotomy.
* Documented coagulations disorders, patients at risk for increased risk of infection (e.g., underlying immunodeficiency including congenital arrythmia), echocardiography evidence of pulmonary hypertension, heparin-induced thrombocytopenia
* Evidence of pruning, lack of pulmonary artery lung distribution, evidence of focal stenosis distal to hilum, aortopulmonary collaterals larger than hilar pulmonary artery diameter or pulmonary artery filling defects
* Children with a low weight for age z score (WAZ) of less than -2.
* Extraordinary obstacles to the ability to follow up regularly include homelessness, parental illness (ongoing medical care, substance abuse, mental illness), or geographical obstacles
* Participation in another clinical trial involving an investigation drug, device, or intervention regardless of potential interference with this study.
* Local or systemic infections will be ruled out by physical exam, vital signs, and a normal white count.
* A period of 2 weeks after treatment of known infection will need to pass prior to having the conduit implanted
